A011-09 PULSAR A Phase 2 Study of Sotatercept for the Treatment of PAH

Investigator: Zeenat Safdar, MD

Study Coordinator: Royanne Holy

Status: Enrolling

ClinicalTrials.gov Number: NCT03496207

Phone: 713.363.7536

Protocol Number: Pro00019405

Description

Study A011-09 is a Phase 2, double-blind, randomized, placebo-controlled, multicenter, parallel-group study to determine the efficacy and safety of sotatercept (ACE-011) plus standard of care (SOC) versus placebo plus SOC in adults with pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1). The study is divided into the Screening Period, double-blind Treatment Period, Extension Period, and Follow-Up Period.
More to Explore